Main Menu
Untitled Page
Home > Equity > Company info > Company Snapshot
18 December 2017

Search Quotes

  Enter at least 3 characters from BSE Code for a company or the company's name

Aurobindo Pharma Ltd (Pharmaceuticals - Indian - Bulk Drugs & Formln)

Last Price 667.60
Net Changes 2.25
Volume 1303384
Prev Close 665.35
667.60 2.25 (0.34%)
Date: Dec 15,2017 EOD




Index Details Pharmaceuticals - Indian - Bulk Drugs & Formln


Chart

Stock Price Details

Market Statistics

Open Price 672.2 Div Yield (%) 0.48
Buy (Size) 0.00(×0) Eps(Rs) 33.4
Sell (Size) 0.00(×0) Book Value(Rs) 160.5349145
Buy Quantity 0 Market Cap(Rs.Cr) 39090.07
Sell Quantity 0 Face Value(Rs) 1
Today's High 676.75 Market Lot 1
Today's Low 664.9 AGM Date Aug
52-Week High 808.95 Book Closure Date Aug
52-Week Low 504 ISIN No. INE406A01037

Share Holding Pattern

  No Of shares % Share Holding
Total Foreign (Promoter & Group) 18000000 3.07
Indian (Promoter & Group) 285925934 48.80
Total of Promoter 303925934 51.87
Non Promoter (Institution) 200056312 34.15
Non Promoter (Non-Institution) 81900163 13.98
Total Non Promoter 281956475 48.13
Total Promoter & Non Promoter 585882409 100.00
Custodians(Against Depository Receipts) 0 0.00
Grand Total 585882409 100.00

Company News

22-Nov-2017  Aurobindo Pharma Limited - Analysts/Institutional Invest...
Aurobindo Pharma Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Aurobindo Pharma Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates
20-Nov-2017  Other announcement of Aurobindo Pharma Ltd.
Other announcement of Aurobindo Pharma Ltd.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herewith enclose notice issued for the attention of equity shareholders of the Company on 15.11.2017 which was published on 18.11.2017, intimating that the equity shares in respect of which dividend remain unclaimed for seven consecutive years, would be transferred to Investor Education and Protection Fund (IEPF), in the following newspapers. Business Standard (English daily) Andhra Prabha (Telugu daily).
20-Nov-2017  Aurobindo Pharma Limited - Updates
Aurobindo Pharma Limited - Updates

Aurobindo Pharma Limited has informed the Exchange regarding 'notice of newspaper publication of transferred to Investor Education and Protection Fund (IEPF)'.
16-Nov-2017  Aurobindo Pharma Limited - Investor Presentation
Aurobindo Pharma Limited - Investor Presentation

Aurobindo Pharma Limited has informed the Exchange regarding Investor Presentation
13-Nov-2017  Other announcement of Aurobindo Pharma Ltd.
Other announcement of Aurobindo Pharma Ltd.

Dilution of Company's ownership in subsidiary, Raidurgam Developers Ltd.
10-Nov-2017  Board of Aurobindo Pharma approves interim dividend of Rs 1.50...
Board of Aurobindo Pharma approves interim dividend of Rs 1.50 per share

The Board of Aurobindo Pharma at its meeting held on 09 November 2017 has approved interim dividend of Rs 1.50 (150%) per share of Re 1 each for FY 2017-18.
10-Nov-2017  Aurobindo Pharma fixes record date for interim dividend
Aurobindo Pharma fixes record date for interim dividend

Aurobindo Pharma has fixed 22 November 2017 as record date for payment of interim dividend. The interim dividend will be paid on or before 30 November 2017.
10-Nov-2017  Aurobindo Pharma drops after announcing Q2 results
Aurobindo Pharma drops after announcing Q2 results

Meanwhile, the S&P BSE Sensex was down 64.52 points or 0.19% at 33,186.41.

On the BSE, 2.18 lakh shares were traded on the counter so far as against the average daily volumes of 2.2 lakh shares in the past one quarter. The stock had hit a high of Rs 808 and a low of Rs 767.50 so far during the day. The stock had hit a 52-week high of Rs 808.95 on 7 November 2017 and a 52-week low of Rs 504 on 29 May 2017.

The stock had outperformed the market over the past one month till 9 November 2017, gaining 8.07% compared with the Sensex's 4.41% rise. The stock had also outperformed the market over the past one quarter, rising 15.35% as against the Sensex's 4.57% rise. The scrip had, however, underperformed the market over the past one year, advancing 3.9% as against the Sensex's 22.01% rise.

The large-cap company has equity capital of Rs 58.59 crore. Face value per share is Re 1.

Aurobindo Pharma's consolidated net profit rise 29% to Rs 781.15 crore on 17.3% rise in net sales to Rs 4354.18 crore in Q2 September 2017 over Q2 September 2016.

Consolidated earnings before interest, tax, depreciation and amortization (EBITDA) margin rose to 25.2% in Q2 September 2017 from 24.6% in Q2 September 2016.

Commenting on the company's performance, N. Govindarajan, Managing Director of the company said that strong growth in US, European Union and growth markets have contributed to a healthy Performance in Q2. Despite challenging environment, US business posted a robust growth of 21% year on year driven by new product launches and increased volumes of existing products. The steady focus on developing a differentiated and speciality product basket will help to sustain the growth momentum for the future, he added.

Aurobindo Pharma's board of directors approved interim dividend of Rs 1.50 per share for the year ending 31 March 2018 (FY 2018).

Separately, the company's board of directors approved to transfer the land admeasuring 24,109 square yards at Raidurg (V), Serilingampalli, Ranga Reddy district to Raidurgam Developers, wholly owned subsidiary of the company for the purpose of development and construction of a commercial building on the same land.

The board also approved the proposal of primary infusion of funds by an investor namely, Aurobindo Realty & Infrastructure, of up to 60% in Raidurgam Developers, resulting in dilution of the Aurobindo Pharma's ownership in Raidurgam Developers to 40% and it consequently ceasing to be the company's subsidiary.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients.

10-Nov-2017  Board of Aurobindo Pharma recommends interim dividend
Board of Aurobindo Pharma recommends interim dividend

Aurobindo Pharma announced that the Board of Directors of the Company at its meeting held on 9 November 2017, inter alia, have recommended the interim dividend of Rs 1.5 per equity Share (i.e. 150%) , subject to the approval of the shareholders.
10-Nov-2017  Aurobindo Pharma consolidated net profit rises 28.98% in the S...
Aurobindo Pharma consolidated net profit rises 28.98% in the September 2017 quarter

Net profit of Aurobindo Pharma rose 28.98% to Rs 781.15 crore in the quarter ended September 2017 as against Rs 605.64 crore during the previous quarter ended September 2016. Sales rose 17.25% to Rs 4354.18 crore in the quarter ended September 2017 as against Rs 3713.58 crore during the previous quarter ended September 2016.

ParticularsQuarter Ended
 Sep. 2017Sep. 2016% Var.
Sales4354.183713.58 17
OPM %25.6525.01 -
PBDT1111.01939.74 18
PBT978.93829.54 18
NP781.15605.64 29
Incorporation Year 1986 
Registered Office Plot No 2 Maitrivihar,Behind Maithri Vanam Ameerpet,
Hyderabad,
Telangana-500038
Telephone 91-40-23736370 
Fax 91-40-23747340 
Chairman K Ragunathan
Managing Director N Govindarajan
Company Secretary B Adi Reddy 
Auditor S R Batliboi & Associates LLP 
Face Value(Rs)
Market Lot
Listing MSEI,BSE,NSE 
Registrar Karvy Computershare Pvt Ltd
Karvy Selenium Tow-B,Pl-31&32 Gachibowli,Nanakramguda,Hyderabad-500032 
Toll Free number: 1800-425-5501 / 1800-103-5501
FINANCIAL TOOLS